reporter | Yin Jingfei
editor |
Taking advantage of the oximeter concept, Kangtai Medical (300869.SZ) stock price has soared. At the close of trading on December 28, Kangtai Medical rose by 17.87%. The turnover rate of and throughout the day reached 27.56%, and the amplitude of and reached 19%. The transaction volume for the whole day was 1.40 billion yuan, with a cumulative increase of 24.73% in the past 5 days and a cumulative increase of 31.84% in the past 30 days.
Not only Kangtai Medical surged on December 28, but the oximeter concept stock surged again. iPeng Medical (300753.SZ), Lexin Medical (300562.SZ) daily limit . Paulite (300246.SZ) rose 12%, Corfu Medical (301087.SZ) rose 10.72%, and Aojiahua (002614.SZ) rose 10%.
Kangtai Medical stated on the interactive platform on December 28 that the company is one of the earliest companies in China to develop, produce and sell oximeter, and is also one of the largest oximeter suppliers in the world. It has a full industry chain production model and has the ability to mass produce oximeter. Recently, the downstream demand for domestic oximeter has surged, and the company has increased its production lines according to the order situation. At present, the daily output of blood oximeters exceeds 100,000 units/set. The company will continue to expand production capacity based on orders and market demand, and do its best to meet order demand.
Data show that blood oxygen saturation is a basic vital sign, reflecting the supply of oxygen to human tissues and organs. The normal value of blood oxygen content in normal people is 95% to 100%. If it is lower than 90%, it often indicates hypoxemia . The "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Ninth Edition)" shows that in a resting state, if the blood oxygen saturation is lower than 93% during inhalation, it can be judged as severe COVID-19. Following , Lianhua Qingwen , antigen reagents, antipyretics, etc., the oximeter has become another best-selling epidemic prevention material.
Dragon Tiger List data shows that on December 28, the sales volume of the sales department seats on the list was 254 million yuan throughout the day, accounting for 17.37% of the total transaction amount on that day. Among them, the buying amount was 113 million yuan, and the selling amount was 141 million yuan, with a total net sales of 28.6074 million yuan. Specifically, institutions bought 17.9113 million yuan and sold 33.4274 million yuan, for a total net sales of 15.5161 million yuan. In addition, the Shenzhen-Hong Kong Stock Connect Special Purpose and Oriental Fortune Securities Lhasa Tuanjie Road Second Securities Sales Department bought 37.5447 million yuan and 20.1997 million yuan respectively; Haitong Securities Mudanjiang Suifenhe Shancheng Road Securities Sales Department and China Galaxy Securities Beijing Zhongguancun Street Securities Sales Department sold 49.1395 million yuan and 16.1383 million yuan respectively.
Although oximeter concept stocks have soared, the performance of related listed companies has been unsatisfactory.
Kangtai Medical achieved operating income of 462 million yuan in the first three quarters, a year-on-year decrease of 35.75%; net profit attributable to shareholders of listed companies was 174 million yuan, a year-on-year decrease of 39.53%;
iPeng Medical's 2022 third quarter report showed that the company's main operating income was 214 million yuan, a year-on-year decrease of 33.88%; net profit attributable to shareholders was -52.233 million yuan, a year-on-year decrease. A decrease of 207.82%;
Lexin Medical achieved operating income of 840 million yuan in the first three quarters of 2022, a year-on-year decrease of 34%. The net profit attributable to shareholders of the listed company was 8.9276 million yuan, dropped 76% year-on-year;
Paulette's net profit in the first three quarters of 2022 was only 10 million yuan, a year-on-year decrease of 85.51%.
